Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies

Executive Summary

Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.

You may also be interested in...

Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA

Biopharma manufacturers dispute predictions that passing through rebates at the point-of-sale in Medicare Part D would increase government spending. Pharmacy benefit managers argue the policy would violate the Part D statute and the Trade Secrets Act.

Targeted Importation: A Drug Pricing Mechanism For 'Predatory Actors' And An A-Pauling HHS Confirmation Dilemma

For those old drug re-pricing situations that reach headline and/or US congressional visibility, a tweak to the importation debate might offer a response.

Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices

During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts